S, Pyykko I, Ishizaki H, Aalto H: Intratympanic gentamicin in Meniere’s disease. Acta Otolaryngol 1998;118:294–298.
80Eklund S, Pyykko I, Aalto H, Ishizaki H, Vasama JP: Effect of intratympanic gentamicin on hearing and tinnitus in Meniere’s disease. Am J Otol 1999;20:350–356.
81Louza JP, Flatz W, Krause E, Gurkov R: Short-term audiologic effect of intratympanic gadolinium contrast agent application in patients with Meniere’s disease. Am J Otolaryngol 2012;33:533–537.
82Louza J, Krause E, Gurkov R: Audiologic evaluation of Meniere’s disease patients one day and one week after intratympanic application of gadolinium contrast agent: our experience in sixty-five patients. Clin Otolaryngol 2013;38:262–266.
83Louza J, Krause E, Gurkov R: Hearing function after intratympanic application of gadolinium-based contrast agent: a long-term evaluation. Laryngoscope 2015;125:2366–2370.
84Yoshioka M, Naganawa S, Sone M, Nakata S, Teranishi M, Nakashima T: Individual differences in the permeability of the round window: evaluating the movement of intratympanic gadolinium into the inner ear. Otol Neurotol 2009;30:645–648.
85Naganawa S, Yamazaki M, Kawai H, Bokura K, Sone M, Nakashima T: Imaging of Meniere’s disease after intravenous administration of single-dose gadodiamide: utility of subtraction images with different inversion time. Magn Reson Med Sci 2012;11:213–219.
86Wu Q, Dai C, Zhao M, Sha Y: The correlation between symptoms of definite Meniere’s disease and endolymphatic hydrops visualized by magnetic resonance imaging. Laryngoscope 2016;126:974–979.
87Yamazaki M, Naganawa S, Tagaya M, Kawai H, Ikeda M, Sone M, et al: Comparison of contrast effect on the cochlear perilymph after intratympanic and intravenous gadolinium injection. AJNR Am J Neuroradiol 2012;33:773–778.
88Naganawa S, Yamazaki M, Kawai H, Bokura K, Sone M, Nakashima T: Visualization of endolymphatic hydrops in Meniere’s disease with single-dose intravenous gadolinium-based contrast media using heavily T(2)-weighted 3D-FLAIR. Magn Reson Med Sci 2010;9:237–242.
89Attye A, Dumas G, Tropres I, Roustit M, Karkas A, Banciu E, et al: Recurrent peripheral vestibulopathy: is MRI useful for the diagnosis of endolymphatic hydrops in clinical practice? Eur Radiol 2015;25:3043–3049.
90Pakdaman MN, Ishiyama G, Ishiyama A, Peng KA, Kim HJ, Pope WB, et al: Blood-labyrinth barrier permeability in meniere disease and idiopathic sudden sensorineural hearing loss: findings on delayed postcontrast 3D-FLAIR MRI. AJNR Am J Neuroradiol 2016, Epub ahead of print.
91Tanigawa T, Tamaki T, Yamamuro O, Tanaka H, Nonoyama H, Shiga A, et al: Visualization of endolymphatic hydrops after administration of a standard dose of an intravenous gadolinium-based contrast agent. Acta Otolaryngol 2011;131:596–601.
92Mukaida T, Sone M, Yoshida T, Kato K, Teranishi M, Naganawa S, et al: Magnetic resonance imaging evaluation of endolymphatic hydrops in cases with otosclerosis. Otol Neurotol 2015;36:1146–1150.
93Gurkov R, Berman A, Dietrich O, Flatz W, Jerin C, Krause E, et al: MR volumetric assessment of endolymphatic hydrops. Eur Radiol 2015;25:585–595.
94Naganawa S: The technical and clinical features of 3D-FLAIR in neuroimaging. Magn Reson Med Sci 2015;14:93–106.
95Naganawa S, Ohashi T, Kanou M, Kuno K, Sone M, Ikeda M: Volume quantification of endolymph after intravenous administration of a single dose of gadolinium contrast agent: comparison of 18- versus 8-min imaging protocols. Magn Reson Med Sci 2015;14:257–262.
96Naganawa S, Kawai H, Taoka T, Sone M: Improved 3D-real inversion recovery: a robust imaging technique for endolymphatic hydrops after intravenous administration of gadolinium. Magn Reson Med Sci 2018, Epub ahead of print.
97Fiorino F, Pizzini FB, Beltramello A, Mattellini B, Barbieri F: Reliability of magnetic resonance imaging performed after intratympanic administration of gadolinium in the identification of endolymphatic hydrops in patients with Meniere’s disease. Otol Neurotol 2011;32:472–477.
98Shi H, Li Y, Yin S, Zou J: The predominant vestibular uptake of gadolinium through the oval window pathway is compromised by endolymphatic hydrops in Meniere’s disease. Otol Neurotol 2014;35:315–322.
99Fiorino F, Pizzini FB, Beltramello A, Barbieri F: Progression of endolymphatic hydrops in Meniere’s disease as evaluated by magnetic resonance imaging. Otol Neurotol 2011;32:1152–1157.
100Gurkov R, Flatz W, Ertl-Wagner B, Krause E: Endolymphatic hydrops in the horizontal semicircular canal: a morphologic correlate for canal paresis in Meniere’s disease. Laryngoscope 2013;123:503–506.
101Jerin C, Krause E, Ertl-Wagner B, Gurkov R: Longitudinal assessment of endolymphatic hydrops with contrast-enhanced magnetic resonance imaging of the labyrinth. Otol Neurotol 2014;35:880–883.
102Suga K, Kato M, Yoshida T, Nishio N, Nakada T, Sugiura S, et al: Changes in endolymphatic hydrops in patients with Meniere’s disease treated conservatively for more than 1 year. Acta Otolaryngol 2015;135:866–870.
103Maxwell R, Jerin C, Gurkov R: Utilisation of multi-frequency VEMPs improves diagnostic accuracy for Meniere’s disease. Eur Arch Otorhinolaryngol 2017;274:85–93.
104Naganawa S, Yamazaki M, Kawai H, Bokura K, Sone M, Nakashima T: Imaging of Meniere’s disease by subtraction of MR cisternography from positive perilymph image. Magn Reson Med Sci 2012;11:303–309.
105Huang CH, Young YH: Bilateral Meniere’s disease assessed by an inner ear test battery. Acta Otolaryngol 2015;135:233–238.
106Friberg U, Stahle J, Svedberg A: The natural course of Meniere’s disease. Acta Otolaryngol Suppl 1984;406:72–77.
107Thomas K, Harrison MS: Long-term follow up of 610 cases of Meniere’s disease. Proc R Soc Med 1971;64:853–857.
